Leming Shi, Ph.D.

Dr. Leming Shi is a professor at the School of Pharmacy and the School of Life Sciences of Fudan University in Shanghai, China where he established the Center for Pharmacogenomics. Dr. Shi’s research focuses on pharmacogenomics, bioinformatics, and cheminformatics aiming to realize personalized medicine by developing biomarkers for early cancer diagnosis and targeted therapy. As a Principal Investigator at the US Food and Drug Administration (FDA) from 2003 to 2012, Dr. Shi conceived and led the MicroArray and Sequencing Quality Control (MAQC/SEQC) project (www.nature.com/nbt/focus/maqc/, www.nature.com/focus/maqc2/, and Nature Biotechnology 2014, in press). Dr. Shi was a co-founder of Chipscreen Biosciences Ltd. in Shenzhen, China where he helped develop a chemogenomics-based drug discovery platform leading to several novel small-molecule drug candidates with promising efficacy and safety profiles in anticancer and antidiabetic clinical trials. Dr. Shi is a co-inventor on nine issued patents about novel therapeutic molecules and has published over 170 peer-reviewed papers (ten of them appeared in Nature Biotechnology). Dr. Shi received his Ph.D. in computational chemistry from the Chinese Academy of Sciences in Beijing, and is a guest faculty at the US FDA and an adjunct professor of medicine at the University of Arkansas for Medical Sciences.